Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours ( NETs ) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly.
A new syringe for Lanreotide autogel / depot ( LAN; Somatuline Autogel o Somatuline Depot ) was developed following feedback from a human factors study to improve ease of injection compared with previous syringes.
PRESTO trial aimed to assess preferences of nurses between the LAN new syringe and the Octreotide long-acting release ( LAR ) syringe.
PRESTO, a multinational, multicentre, prospective, noninterventional, simulated-use study, enrolled nurses with 2 years or more experience injecting Lanreotide autogel / depot and/or Octreotide LAR in patients with NETs and/or acromegaly.
Nurses administered injections into pads using the Lanreotide autogel / depot new syringe and Octreotide LAR syringe in a randomised sequence.
In an anonymous web-based questionnaire, nurses reported their overall preference ( strong or slight; primary endpoint ) and rated and ranked the importance of nine attributes for each syringe ( 1 [ not at all ] to 5 [ very much ] ).
Overall, 90 nurses attended sessions and completed valid questionnaires. Most nurses ( 97.8% ) expressed a preference ( 85.6% strong, 12.2% slight ) for the Lanreotide autogel / depot new syringe versus the Octreotide LAR syringe ( P less than 0.0001 ).
Attribute performance ratings ( 1 [ not at all ] to 5 [ very much ] ) were consistently higher for the Lanreotide autogel / depot new syringe versus the Octreotide LAR syringe, with the greatest differences in fast administration and confidence the syringe will not be clogged ( mean difference [SD]: 2.6 [1.2] and 2.3 [1.5], respectively; P less than 0.0001 ).
The attribute ranked most important was confidence the syringe will not be clogged ( 24.4% ); least important was convenience of syringe format, including packaging, from preparation to injection ( 34.4% ).
In conclusion, nurses preferred the user experience of the Lanreotide autogel / depot new syringe compared with the Octreotide LAR syringe, with a particular preference for attributes related to product delivery with the LAN new syringe. ( Xagena )
Adelman, D et al, Adv Ther 2020. doi.org/10.1007/s12325-020-01255-8